Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre by Variola, Angela et al.
93© 2017 The Authors. Published by SEEd srl. This is an open access article under the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)
cases [2]. These diseases mainly affect the 
age range 15-40 years [3]. In particular, UC 
shows the highest incidence between 20 and 
40 years, while Crohn’s disease in the age 
range 15-35 years [3]. Men and women are 
equally affected [4]. Like most chronic dis-
eases, IBD results in a significant reduction 
in the quality of life [5], while representing 
a high consumption of healthcare resources 
(drugs, hospitalizations, etc.) [6,7].
IntroductIon
Inflammatory Bowel Disease (IBD) is a 
group of conditions characterized by an 
immune-mediated, systemic and chronic in-
flammation of the gastrointestinal tract, and 
includes Ulcerative Colitis (UC) and Crohn’s 
Disease (CD) [1]. In Italy, the number of pa-
tients suffering from IBD can be estimated 
at between 150,000-200,000 cases, with an 
annual incidence of approximately 10,000 
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AbstrAct
BACKGROUND: Inflammatory bowel disease (IBD) represents a group of chronic conditions characterized by elevated 
costs. Over the last years, also a considerable healthcare burden associated with IBD has emerged, due to an increasing use 
of biological drugs and hospitalization costs. Despite the creation of local or regional databases, data regarding healthcare 
expenditure are lacking in Italy.
AIM: To evaluate the treatment cost (biological drugs and hospitalizations) for patients with ulcerative colitis (UC) or 
Crohn’s disease (CD) treated with biological drugs.
METHODS: Disease severity was evaluated by clinical scores (partial Mayo score and Harvey Bradshaw Index). We 
analyzed retrospectively patients treated with biologics referred to our IBD Unit between May 2015-April 2016 who un-
derwent at least six months of follow-up (last visit October 2016). We calculated a mean cost per month of treatment for 
each patient. We also investigated the presence of any correlation between the monthly cost of treatment and demographic 
or clinical variables.
RESULTS: We enrolled 142 patients (52 UC, mean age 44.3 years, male 40.4%; 90 CD, mean age 38.8 years, male 56.7%). 
About half of CD patients (48.9%) underwent previous intestinal surgery. The disease severity was higher in UC group vs 
CD group. In UC group infliximab was the most prescribed biologic (51.9%), followed by golimumab (26.9%) and adali-
mumab (21.2%). While CD patients were treated with adalimumab in 54.4% and infliximab in 45.6%. The mean monthly 
cost of treatment was € 1,235.41 ± 358.38 for UC and € 1,148.92 ± 337.36 for CD (p = 0.16). In both groups expenditure 
due to biologics amounts for more than 80%. We found a correlation between costs and disease activity (UC: p < 0.01; CD: 
p < 0.01).
CONCLUSION: The main cost is due to biological drugs, but patients enrolled were the most severe in comparison to the 
whole IBD population under conventional therapy. As no cost differences were found between biologic drugs and the way 
of administration (intravenous or subcutaneous), the therapeutic choice should be driven by clinical reasons and not only 
economic ones. 
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The clinical spectrum of IBD is very broad, 
and ranges from asymptomatic to serious 
disease states. Although the etiology of IBD 
has not yet been well defined, aspects such 
as genetics, intestinal microbiome and the 
immunomodulatory responses influenced 
by the environment are the target of the new 
therapies [8]. The therapies currently ap-
proved for the treatment of UC or CD, whose 
goal is to reduce the inflammatory status, 
include aminosalicylates, corticosteroids, 
immunomodulators and biological drugs 
[9,10]. The latter may be divided into two 
main categories: anti-tumor necrosis factor 
(anti-TNF) drugs (eg. infliximab, adalim-
umab, golimumab) and anti-integrin drugs 
(vedolizumab) [1,11]. With the increased 
use of biologics, more expensive than stan-
dard therapies, the expenditure generated 
by IBD increased: UC and CD also gener-
ate a significant economic impact, both for 
the individual patient and for the Healthcare 
System [11-15].
The necessity for a more targeted control of 
healthcare spending generated the need to 
have detailed information on the consump-
tions and costs related to the single diseases. 
However, despite the presence in Italy of nu-
merous local or regional administrative data-
bases, such information is often not available, 
or partly incomplete (due to the adminis-
trative nature of the databases, the demo-
graphic and clinical information needed for 
the characterization of patients are limited). 
As a result of this scenario, the current level 
of knowledge about healthcare costs and the 
profiles of patients with IBD is very low.
The purpose of this analysis is to define the 
treatment cost (biologics and hospitaliza-
tions) associated with a group of patients 
with UC or CD referred to a Center located 
in Northeastern Italy, and examine this cost 
compared to some demographic and clinical 
variables.
Methods
setting and analysis perspective
The investigative scope of this analysis is 
represented by the population referred to the 
Multi-specialist Center for Rectal-Intestinal 
Diseases of the Ospedale Sacro Cuore – Don 
Calabria di Negrar (hereinafter simply re-
ferred to as the “Center”), located in North-
eastern Italy.
The cost analysis was carried out by adopting 
the perspective of the Italian National Health 
Service (NHS), thus considering only direct 
medical costs (biological drugs and hospital-
izations).
Data source and 
definition of sample
The retrospective, observational and non-in-
terventional analysis considered all subjects 
who, diagnosed with UC or CD and treated 
with biological drugs, were referred to the 
Center during the period May 2015-April 
2016. The cases were identified retrospec-
tively, thanks to the access to the archives of 
the Center. Each patient enrolled was subject-
ed to a follow-up of at least six months. The 
follow-up was concluded in October 2016.
The archives of the Center allowed to recover 
for each patient a series of demographic and 
clinical information, plus other information 
on the consumption of resources, as detailed 
below. The diagnosis of UC or CD was clini-
cally confirmed on the basis of what indicat-
ed in the medical records. Patients with other 
diagnoses (eg. diverticulitis) were excluded.
Demographic and clinical data
The detailed demographic and clinical data 
was extrapolated from the records contained 
in the archives of the Center. These include 
age, gender, weight, type of IBD (UC or CD) 
and age of onset, duration, severity and site 
of the disease. For UC the disease site was 
coded as pancolitis, left colitis, proctitis or 
ileal colitis, while for CD the ileocolic, ileal, 
colic or proctitis sites were coded.
Two different scales were considered to eval-
uate the severity of IBD: the Mayo Score for 
UC [16,17] and the Harvey-Bradshaw Index 
(HBI) for CD [19]. Considering four compo-
nents (defecation frequency, rectal bleeding, 
endoscopic evaluation and overall assess-
ment), the Mayo Score defines the severity 
of the disease using four discrete states: i) 
remission, ii) mild activity, iii) moderate ac-
tivity, and iv) serious activity [16,17]. On the 
basis of five exclusively clinical parameters 
(patient well-being, abdominal pain, num-
ber of liquid or soft evacuations, abdominal 
mass, presence of complications), the HBI 
also defines the severity of the disease, us-
ing the same four discrete states of the Mayo 
Score (remission, mild activity, moderate ac-
tivity and severe activity) [19,20].
Consumption and costs 
of resources
Information about health resources consumed 
by patients along the observation period were 
also extrapolated from the records of the ar-
chives of the Center. Only the resources used 
for the treatment of UC or CD were included. 
In particular, biological drugs and hospital-
izations finalized to the management of the 
two diseases were considered. For each bio-
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fore identified: i) first-line treatment (use of 
a single biological drug during the observa-
tion period), ii) second-line treatment (use of 
two biological drugs during the observation 
period) and iii) third-line treatment (use of 
three biological drugs during the observation 
period). Since in some cases the patient may 
discontinue the biological treatment without 
then beginning a subsequent one (eg. surgery, 
auto-suspension, etc.) other two classes were 
added: iv) second-line treatment without any 
subsequent biological drug and v) third-line 
treatment without any subsequent biological 
drug. The second analysis proposed is instead 
aimed at identifying any differences between 
the costs per month of treatment, depending 
on the type of administration of the biologi-
cal drug (subcutaneous or intravenous). Fi-
nally, in the third analysis we tried, where 
possible, to define homogeneous subgroups 
(same route of administration, same severity, 
exclusion of patients with surgery or prior ad-
ministration of biological drugs) in order to 
investigate the presence of differences in the 
mean cost per month of treatment depending 
on the active ingredient administered.
Data analysis
Quantitative variables have been described as 
mean value (± standard deviation), categori-
cal variables as numeric value (percentage). 
The significance of the differences between 
the data found/processed was verified by ap-
plying the Student’s two-tailed t-test. The 
correlations between the data found/pro-
cessed was verified by applying the Pearson’s 
two-tailed r-test. The analysis was supported 
by Microsoft® Excel® for Windows® (Mi-
crosoft Corporation, Seattle, WA, USA) and 
SPSS® 13.0 for Windows® (SPSS Inc., Chi-
cago, IL, USA).
results
Characteristics of the sample
During the enrollment period, 144 patients 
diagnosed with IBD were referred to the Cen-
ter. Of these, two patients (both diagnosed 
with CD) did not meet the inclusion crite-
ria, since the relevant follow-up period was 
less than six months. Overall, in the analysis 
142 patients were then considered, including 
52 with a diagnosis of UC (mean age: 44.3 
± 13.7 years; males: 40.4%; weight: 70.8 ± 
14.1 kg), and 90 diagnosed with CD (mean 
age: 38.8 ± 13.9 years; males: 56.7%; weight: 
69.4 ± 15.5 kg). In both cases the number of 
people suffering from UC or CD reached the 
maximum concentration in the age range 19-
45 years (UC: 57.7%; CD: 63.3%), to gradul-
logical drug the date of beginning and end of 
administration, the presence of induction (if 
the first administration of the biological drug 
occurred concomitantly with or after the date 
of enrollment), the dose administered, the 
number of infusions and the possible reason 
for suspension were indicated. The admitting 
department, the hospitalization length and 
the related diagnosis-related group (DRG) 
were instead indicated for each hospitaliza-
tion.
Upon their enrollment, patients were admin-
istered one of the following biological drugs: 
i) adalimumab subcutaneously (SC), with the 
double indication for UC and CD, ii) golim-
umab SC with the sole indication for UC and 
iii) infliximab intravenous (IV) with the dou-
ble indication for UC and CD. The cost of the 
biological drugs was calculated by detecting 
for each individual patient the actual cost in-
curred by the hospital pharmacy of the Cen-
ter. For each biological drug, it was then con-
sidered the relative purchase price, net of all 
discounts (mandatory and not). These prices, 
being referred to a period of 18 months, in 
fact reflect the relative average price paid by 
the hospital pharmacy. For adalimumab it 
was therefore considered an average price of 
€ 491.50 for a 40 mg pre-filled pen, while for 
golimumab an average price of € 1,038.33 
was used both for the 100 mg and the 50 mg 
pre-filled pens. The average price per milli-
gram of infliximab amounted to € 4.05. Fi-
nally, hospitalizations were quantified thanks 
to the relevant DRG rates [21].
analysis of the costs of treatment
On the basis of the data collected, as a first 
objective of this analysis an average treat-
ment cost in relation to the two IBDs was 
estimated. Since, on the basis of the enroll-
ment criteria, the follow-up for each patient 
may vary from a minimum of six months to 
a maximum of 18 months, it was decided to 
present the data in the form of mean cost per 
month of treatment, thus avoiding any ex-
trapolation bias (eg. at Month 12, 18 or 24). 
This cost was calculated by dividing the total 
treatment cost associated with each patient 
(biological drugs and hospitalizations) by the 
relevant number of months of follow-up.
The mean cost per month of treatment was 
then investigated, in light of other variables 
such as gender, age, comorbidities, treat-
ment lines, route of administration and active 
ingredient. The last three types of analysis 
proposed deserve a more in-depth examina-
tion. In the first of these, we tried to verify 
whether the switch to a second and/or third 
line of treatment could result in an increase in 
the treatment cost. Three classes were there-
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CD, while the average disease duration was 
8.5 ± 8.2 years for UC and 9.2 ± 7.7 years 
for CD.
The main clinical characteristics are summa-
rized in Table I. The presence of one or more 
comorbidities was documented in 27% of the 
cases of UC and in 25.6% of cases of CD. 
In both groups the most frequent comorbidity 
was arterial hypertension (UC: 12.0%; CD: 
7.8%). Extra-intestinal manifestations were 
present in 17.3% of patients with UC and in 
25.6% of those with CD. Almost half of the 
sample of patients with CD (48.9%) were 
characterized by a prior surgical history; 
while in the ulcerative colitis group no sur-
gery had been carried out before enrollment.
Figure 2 shows the severity of IBD upon en-
rollment. A picture emerges of a more com-
promised disease activity in patients with UC 
than in those with CD.
Treatments administered
98.1% of patients with UC and 91.1% of 
those with CD received a previous treatment 
with steroids (Table I). Upon enrollment, 
patients treated with steroids with a diag-
nosis of UC and CD are 27 (51.9%) and 76 
(84.4%), respectively (Table I). Upon enroll-
ment, 21.2% of patients with UC and 44.4% 
of those with CD were already being treated 
with a biologic for an average duration of 3.9 
± 10.9 months and 12.8 ± 17.9, respectively.
The follow-up period was 13.1 ± 4.0 months 
for patients with UC and 14.7 ± 3.2 months 
for those with CD. During this period, four 
patients with a diagnosis of CD (4.4%) 
achieved a remission. During the follow-up 
period, 46.2% of patients with UC changed 
or discontinued the biological drug received 
upon enrollment; this also happened in 34.4% 
of patients with CD. The most frequent rea-
son for switch/discontinuation was therapeu-
tic failure (UC: 79.2%; CD: 58.1%).
Just under half (48.1%) of the subjects with 
UC was being treated with a biologic ad-
ministered subcutaneously, while in patients 
with CD this percentage was just over half 
(54.4%). Both for UC and CD, the treatment 
with a biologic administered intravenously 
(infliximab) was characterized by a higher 
concentration of patients in the severity class 
compared to the biological drug administered 
subcutaneously (Table II). With reference to 
UC – the only setting in which the subcuta-
neous indication for both biological drugs 
was present – the subjects being treated with 
adalimumab showed a severity from remis-
sion to moderate, while those treated with go-
limumab a severity from moderate to severe 
(Table II).
Characteristics 
(at enrollment)
UC (n. = 52) CD (n. = 90)
Site of disease, n. (%)
Pancolitis: 25 (48.1) Ileocolic: 47 (52.2)
Left colitis: 22 (42.3) Ileal: 25 (27.8)
Proctitis: 4 (7.7) Colic: 17 (18.9)
Ileal colitis: 1 (1.9) Proctitis: 1 (1.1)
Comorbidities, n. (%)
 • No 38 (73.1) 67 (74.4)
 • 1 11 (21.2) 18 (20.0)
 • 2 or more 3 (5.8) 5 (5.6)
Comorbidities, mean ± SD 0.40 ± 0.87 0.37 ± 0.79
Extra-intestinal manifestations, n. (%)
 • No 43 (82.7) 67 (74.4)
 • 1 8 (15.4) 18 (20.0)
 • 2 or more 1 (1.9) 5 (5.6)
Extra-intestinal manifestations, 
mean ± SD
0.21 ± 0.54 0.31 ± 0.57
Previous treatment with 
steroids, n. (%)
51 (98.1) 82 (91.1)
Previous treatment with 
steroids, mean duration 
(months) ± SD
13.7 ± 18.5 11.4 ± 28.3
Steroids at enrollment, n. (%) 27 (51.9) 76 (84.4)
Previous treatment with 
biological drugs, n. (%)
11 (21.2) 40 (44.4)
Previous treatment with 
biological drugs, mean 
duration (months) ± SD
3.9 (± 10.2) 12.8 (± 17.9)
Previous surgery, n. (%) 0 (0.0) 44 (48.9)
Table I. Main clinical characteristics of enrolled patients (n. = 142)
CD = Crohn’s disease; UC = ulcerative colitis
Figure 1. Stratification by age group
Figure 2. Severity of IBD upon enrollment
ly decrease in more advanced age groups 
(46-65 years and 66-75 years) (Figure 1). The 
mean age of the onset of disease was 35.7 ± 
13.3 years for UC and 29.5 ± 14.1 years for 
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morbidities: € 1,174.64 ± 385.23; absence 
of comorbidities: € 1,140.09 ± 321.38; p 
= 0.71). Figures 4 and 5 show, for UC and 
CD, respectively, the mean cost per month of 
treatment divided by the number of lines of 
treatment administered during follow-up. In 
patients with UC or with CD a correlation (p 
< 0.01) emerges between the increase in costs 
and the growing number of biological drugs 
administered.
Stratification by route of administration (IV 
vs SC) of the mean cost per month of treat-
ment showed no significant differences in UC 
Infliximab (51.9%) was the biological drug 
most commonly prescribed for patients di-
agnosed with UC, followed by golimumab 
(26.9%) and adalimumab (21.2%). Adalim-
umab was the biologic most frequently used 
for patients with CD (54.4%), followed by 
infliximab (45.6%).
Treatment Cost
The mean cost per month of treatment 
amounted to € 1,235.41 ± 358.38 for patients 
with UC and to € 1,148.92 ± 337.36 for those 
with CD (Table III). In both cases, the cost 
item associated with the consumption of bio-
logical drugs covers over 80% of the mean 
overall cost. The difference in the mean cost 
between the two IBDs (€ 86.49) was not sta-
tistically significant (p = 0.16).
For both UC (males: € 1,334.14 ± 327.30; 
females: € 1,168.53 ± 368.08) and for CD 
(males: € 1,207.59 ± 341.14; females: € 
1,072.19 ± 325.64) the mean monthly treat-
ment cost calculated for males was higher 
than that for females; the differences are not 
significant (UC: € 165.61 p = 0.10; CD: € 
135.41 p = 0.06).
Crossing the variables “age group” and “treat-
ment cost” did not show any correlation. On 
the contrary, Figure 3 shows a significant (p 
< 0.01) correlation for both UC and for CD 
between the mean cost per month of treat-
ment and the severity class: the increasing 
of the latter increases the cost of treatment. 
The presence of comorbidities upon enroll-
ment determines a slight and non-significant 
increase in the cost of treatment for both UC 
(presence of comorbidities: € 1,275.05 ± 
181.03; absence of comorbidities: € 1,220.81 
± 405.18; p = 0.52) and CD (presence of co-
 
 
severity (% pts)
remission Mild Moderate severe
UC
 • IV 0.0 11.1 51.9 37.0
 • SC 8.0 8.0 60.0 24.0
 • Adalimumab 18.2 18.2 63.6 0.0
 • Golimumab 0.0 0.0 57.1 42.9
CD
 • IV 4.9 31.7 48.8 14.6
 • SC 18.4 42.9 34.7 4.1
Table II. Patients distribution by severity and route of administration
CD = Crohn’s disease; IV = intravenous; SC = subcutaneous; UC = ulcerative colitis
Cost item UC CD
Biological drugs 1,019.82 1,002.81
Hospitalization 215.59 146.11
Total 1,235.41 1,148.92
Table III. Mean monthly treatment cost
CD = Crohn’s disease; UC = ulcerative colitis
CD, while the average disease duration was 
8.5 ± 8.2 years for UC and 9.2 ± 7.7 years 
for CD.
The main clinical characteristics are summa-
rized in Table I. The presence of one or more 
comorbidities was documented in 27% of the 
cases of UC and in 25.6% of cases of CD. 
In both groups the most frequent comorbidity 
was arterial hypertension (UC: 12.0%; CD: 
7.8%). Extra-intestinal manifestations were 
present in 17.3% of patients with UC and in 
25.6% of those with CD. Almost half of the 
sample of patients with CD (48.9%) were 
characterized by a prior surgical history; 
while in the ulcerative colitis group no sur-
gery had been carried out before enrollment.
Figure 2 shows the severity of IBD upon en-
rollment. A picture emerges of a more com-
promised disease activity in patients with UC 
than in those with CD.
Treatments administered
98.1% of patients with UC and 91.1% of 
those with CD received a previous treatment 
with steroids (Table I). Upon enrollment, 
patients treated with steroids with a diag-
nosis of UC and CD are 27 (51.9%) and 76 
(84.4%), respectively (Table I). Upon enroll-
ment, 21.2% of patients with UC and 44.4% 
of those with CD were already being treated 
with a biologic for an average duration of 3.9 
± 10.9 months and 12.8 ± 17.9, respectively.
The follow-up period was 13.1 ± 4.0 months 
for patients with UC and 14.7 ± 3.2 months 
for those with CD. During this period, four 
patients with a diagnosis of CD (4.4%) 
achieved a remission. During the follow-up 
period, 46.2% of patients with UC changed 
or discontinued the biological drug received 
upon enrollment; this also happened in 34.4% 
of patients with CD. The most frequent rea-
son for switch/discontinuation was therapeu-
tic failure (UC: 79.2%; CD: 58.1%).
Just under half (48.1%) of the subjects with 
UC was being treated with a biologic ad-
ministered subcutaneously, while in patients 
with CD this percentage was just over half 
(54.4%). Both for UC and CD, the treatment 
with a biologic administered intravenously 
(infliximab) was characterized by a higher 
concentration of patients in the severity class 
compared to the biological drug administered 
subcutaneously (Table II). With reference to 
UC – the only setting in which the subcuta-
neous indication for both biological drugs 
was present – the subjects being treated with 
adalimumab showed a severity from remis-
sion to moderate, while those treated with go-
limumab a severity from moderate to severe 
(Table II).
Characteristics 
(at enrollment)
UC (n. = 52) CD (n. = 90)
Site of disease, n. (%)
Pancolitis: 25 (48.1) Ileocolic: 47 (52.2)
Left colitis: 22 (42.3) Ileal: 25 (27.8)
Proctitis: 4 (7.7) Colic: 17 (18.9)
Ileal colitis: 1 (1.9) Proctitis: 1 (1.1)
Comorbidities, n. (%)
 • No 38 (73.1) 67 (74.4)
 • 1 11 (21.2) 18 (20.0)
 • 2 or more 3 (5.8) 5 (5.6)
Comorbidities, mean ± SD 0.40 ± 0.87 0.37 ± 0.79
Extra-intestinal manifestations, n. (%)
 • No 43 (82.7) 67 (74.4)
 • 1 8 (15.4) 18 (20.0)
 • 2 or more 1 (1.9) 5 (5.6)
Extra-intestinal manifestations, 
mean ± SD
0.21 ± 0.54 0.31 ± 0.57
Previous treatment with 
steroids, n. (%)
51 (98.1) 82 (91.1)
Previous treatment with 
steroids, mean duration 
(months) ± SD
13.7 ± 18.5 11.4 ± 28.3
Steroids at enrollment, n. (%) 27 (51.9) 76 (84.4)
Previous treatment with 
biological drugs, n. (%)
11 (21.2) 40 (44.4)
Previous treatment with 
biological drugs, mean 
duration (months) ± SD
3.9 (± 10.2) 12.8 (± 17.9)
Previous surgery, n. (%) 0 (0.0) 44 (48.9)
Table I. Main clinical characteristics of enrolled patients (n. = 142)
CD = Crohn’s disease; UC = ulcerative colitis
Figure 1. Stratification by age group
Figure 2. Severity of IBD upon enrollment
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(p = 0.99) or CD patients (p = 0.98) (Table 
IV). Finally, Table V presents the results of 
the only possible comparison between homo-
geneous treatment groups, divided according 
to the active principle administered upon en-
rollment. Since infliximab is the only active 
principle administered intravenously and go-
limumab is not indicated in the treatment of 
CD, the analysis is limited to the comparison 
between adalimumab and golimumab in the 
treatment of UC. In this specific case, the 
comparison was made considering the “mod-
erate” severity class only, since it was the 
only one characterized by the presence of pa-
tients treated with adalimumab or golimumab 
(Table II). Excluding the subjects with a prior 
surgical or biological history, the comparison 
was made considering 7 patients treated with 
adalimumab and 6 with golimumab (Table V). 
The difference in the mean cost per month of 
treatment (€ 69.18) between adalimumab and 
golimumab was not statistically significant (p 
= 0.45). The higher mean cost of the biologi-
cal drug associated with adalimumab is offset 
by the lower number of hospitalizations. This 
increased number of hospitalizations of the 
patients who start treatment with golimumab 
may be a consequence of the longer disease 
duration (10.1 years vs 4.1 years, p = 0.21).
dIscussIon
This retrospective, observational study was 
conducted with the aim to estimate the cost 
of the disease associated with patients with a 
diagnosis of UC or CD in Italy. The sample 
base, consisting of 142 patients (mean age 
40.8 ± 14.0 years), was constructed enroll-
ing all patients who, with a diagnosis of UC 
or CD and in treatment with biologics, were 
referred to the Center during the period May 
2015-April 2016.
The mean cost per month of treatment 
was consistent for the two diseases (UC: € 
1,235.41 ± 358.38; CD: € 1,148.92 ± 337.36; 
p = 0.16). In both groups, the main cost item 
is represented by biologics (more than 80% 
of the total). Overall, that is both for UC and 
for CD, the mean cost per month of treatment 
increases with the severity of the disease. It 
is also notable how the cost item associated 
with hospitalizations grows with the increase 
in severity, going – as expressed as an inci-
dence on the total cost – from 0% for the re-
mission to 26-30% for the severe status. The 
mean cost per month of treatment also grows 
with the increase in the number of treatment 
lines (p < 0.01).
Figure 3. Correlation between the mean monthly cost and severity of disease
Figure 5. Mean cost per line of treatment (Crohn’s disease)
Figure 4. Mean cost per line of treatment (ulcerative colitis)
UC CD
IV sC IV sC
Patients, n. 27 25 41 49
Mean age, years 43,4 45,2 42,9 35,3
Mean disease duration, 
years
9,8 7,1 9,4 9,1
Mean follow-up, months 13,0 13,1 14,5 14,9
Mean monthly cost, 
€ (SD)
1,234.99 
(412.31)
1,235.87 
(297.93)
1,149.93 
(384.18)
1,148.07 
(296.70)
Table IV. Mean cost per month of treatment: subcutaneous (SC) vs intravenous 
(IV) administration
CD = Crohn’s disease; IV = intravenous; SC = subcutaneous; SD = standard deviation; 
UC = ulcerative colitis
Biologic at enrollment
adalimumab golimumab
Diagnosis UC CD
Patients, n. 7 6
Age, years 42.6 48.7
Disease duration, years 4.1 10.0
Previous treatment with biologic No No
Previous surgery No No
Severity of disease Moderate Moderate
Follow-up, months 11.1 10.3
Biologic cost, €/month 1,310.08 1,285.62
Hospitalization cost, €/ month 0.00 93.65
Total cost, €/month (SD) 1,310.08 (125.50) 1,379.26 (161.73)
Table V. Mean cost per month of treatment: adalimumab vs golimumab
CD = Crohn’s disease; SD = standard deviation; UC = ulcerative colitis
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Further analyses conducted between cost, 
route of administration and active ingredients 
did not show any appreciable difference. Al-
though the comparison of the mean cost as-
sociated with biological drugs administered 
subcutaneously, compared to intravenously, 
did not show any significant differences, it 
should be noted that the biologics given in-
travenously, however, require a greater in-
vestment in terms of time by both the health-
care professional and the patient.
The distribution of patients by severity would 
seem to bring out some differences in the 
choice of the biological therapy administered. 
Intravenous biological therapy would appear 
to be administered to more compromised pa-
tients; while between the two biological drugs 
administered subcutaneously in UC, golimum-
ab would seem to be used more frequently in 
subjects with a longer and more severe history 
of disease than those treated with adalimumab.
Finally, with regard to the average purchase 
prices of the biologics considered here, it 
should be noted that for adalimumab and go-
limumab the current sales price decreased by 
5.0% and 3.1%, respectively. The application 
of these discounts, however, would not sig-
nificantly modify the results proposed here.
Among the limitations attributable to this 
analysis, some should be highlighted. First, 
the sample refers to a single Center. Unfor-
tunately, there are no elements to establish 
to which extent it could be considered repre-
sentative of the entire Italian reality, or how 
over- or under-estimated, with respect to the 
latter, could be the costs of the disease re-
ported in this study. The availability of a few 
other center would have made it possible to 
ascertain the degree of information disparity 
existing between each of them.
Second, the enrollment sample was not di-
mensioned in order to have a certain preci-
sion in the estimation of the average cost in 
the two main groups (UC and CD), although 
was made considering 7 patients treated with 
adalimumab and 6 with golimumab (Table V). 
The difference in the mean cost per month of 
treatment (€ 69.18) between adalimumab and 
golimumab was not statistically significant (p 
= 0.45). The higher mean cost of the biologi-
cal drug associated with adalimumab is offset 
by the lower number of hospitalizations. This 
increased number of hospitalizations of the 
patients who start treatment with golimumab 
may be a consequence of the longer disease 
duration (10.1 years vs 4.1 years, p = 0.21).
dIscussIon
This retrospective, observational study was 
conducted with the aim to estimate the cost 
of the disease associated with patients with a 
diagnosis of UC or CD in Italy. The sample 
base, consisting of 142 patients (mean age 
40.8 ± 14.0 years), was constructed enroll-
ing all patients who, with a diagnosis of UC 
or CD and in treatment with biologics, were 
referred to the Center during the period May 
2015-April 2016.
The mean cost per month of treatment 
was consistent for the two diseases (UC: € 
1,235.41 ± 358.38; CD: € 1,148.92 ± 337.36; 
p = 0.16). In both groups, the main cost item 
is represented by biologics (more than 80% 
of the total). Overall, that is both for UC and 
for CD, the mean cost per month of treatment 
increases with the severity of the disease. It 
is also notable how the cost item associated 
with hospitalizations grows with the increase 
in severity, going – as expressed as an inci-
dence on the total cost – from 0% for the re-
mission to 26-30% for the severe status. The 
mean cost per month of treatment also grows 
with the increase in the number of treatment 
lines (p < 0.01).
Figure 3. Correlation between the mean monthly cost and severity of disease
Figure 5. Mean cost per line of treatment (Crohn’s disease)
Figure 4. Mean cost per line of treatment (ulcerative colitis)
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with those estimated by a recent analysis 
conducted in the United States [23]. The 
American analysis compared the direct medi-
cal costs associated with 539 patients with 
CD to a control group without any diagnosis 
of IBD. The average annual cost per patient 
with CD amounted to US $ 13,446, against 
the US $ 6,029 associated with subjects with-
out IBD. If recalculated on a monthly basis 
(US $ 1,120.5), the average cost estimated by 
the American study comes to have an order 
of magnitude similar to that estimated here 
(CD: € 1,148.92).
Finally, it is also interesting the comparison 
with the average costs by severity calculated 
from a recent analysis conducted in Australia 
on 175 patients with UC [24]. The average 
direct healthcare cost calculated over a time 
horizon of three months of treatment was AU 
$ 2,914. The analysis conducted by severity 
reported costs rising with the increase in se-
verity (remission: AU $ 1,970; mild activity: 
AU $ 3,736 and moderate/severe activity: 
AU $ 4,162). These data confirm what was 
found here: the importance of severity as a 
cost driver.
conclusIons
The data collected and presented here, albeit 
limited to a single experience referred to a 
Center in Northeast Italy, would seem suf-
ficient to state that both UC and CD are pa-
thologies characterized by an overall rather 
high cost borne by the National Health Ser-
vice, and that, due to chronicity, this cost is 
likely to increase with the progression of the 
severity of the conditions.
From the treatment cost data, a further indi-
cation would finally seems to emerge, to be 
kept in mind during the biological treatment 
selection process. Since the various compari-
sons carried out (SC therapy vs IV therapy; 
adalimumab vs golimumab) showed no sig-
nificant differences between the costs of 
treatment, it is believed that the choice of the 
biological drug should be made taking into 
greater account the clinical aspects, and that 
therefore the cost of treatment would not be 
the only choice driver.
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the variability of the costs appeared to be 
contained. Therefore, the dimension of the 
subgroups were also limited. Probably also 
for this reason some of the differences found 
in the analysis were found to be significant. 
It should however be clarified that the study 
had no objectives in this sense, nor the sam-
ple was dimensioned in terms of statistical 
power.
Third, the cost analysis collected information 
only on the costs determined by biological 
therapy and hospitalizations; other cost items 
were not considered (eg. specialist visits, 
etc.), which however are potentially interest-
ing for those wishing to examine in detail the 
knowledge of the resources required by UC 
or CD. In this respect, it is to be emphasized 
that the choice of a therapy administered sub-
cutaneously or intravenously may result in a 
different economic impact borne both by the 
hospital – expressed in terms of time dedi-
cated by doctors and nurses – and the patient 
(and/or caregiver) – expressed in terms of 
reduced work performance (number of work-
ing days lost due to the disease).
The treatment of IBD represents a signifi-
cant burden from all perspectives, especially 
when considering the NHS’s and the soci-
ety’s in its entirety. A recent European study 
(ECCO-EpiCom Study) estimated the cost of 
treating patients with IBD in the first year of 
diagnosis [22].The study enrolled 1,367 pa-
tients referred to 31 Hospital Centers located 
in Western (WE) and Eastern Europe (EE), 
710 of whom diagnosed with UC, 509 with 
CD and 148 with unspecified IBD. The total 
expenditure associated with the entire cohort 
was € 5,408,174 (diagnostics: € 2,042,990 
[38%], surgery: € 1,427,648 [26%], biolog-
ics: € 781,089 [14%] and standard therapy: € 
1,156,520 [22%]), with an average cost of € 
3,956.23 (recalculated on a monthly basis as 
equal to € 369.69). The significant difference 
in the cost of treatment that emerges compared 
to what was found here is mainly due to the 
heterogeneity of the two cohorts considered. 
In this analysis only patients receiving biolog-
ics with a history of disease established over 
time (about 9 years on average) were consid-
ered. On the contrary, patients enrolled in the 
European study are in the first year of treat-
ment, and therefore make a lesser use of the 
biological therapy (average cost recalculated 
on a monthly basis: € 47.16) and of surgery 
(average annual cost per patient: € 87.03).
The results estimated here, with the neces-
sary limitations, would seem to be in line 
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